

UNITED STATES OF AMERICA
FEDERAL TRADE COMMISSION

WASHINGTON, D.C. 20580



Division of Advertising Practices

June 19, 2014

Andrea C. Levine, Esq.
Senior Vice President, Director
National Advertising Division
112 Madison Avenue, 3rd Floor
New York, NY 10016

Re: MiMedx Group, Inc.

Dear Ms. Levine:

I am writing to follow up on your May 15, 2014 letter referring an NAD investigation into advertising claims for the MiMedx Group, Inc.'s EpiFix and EpiFix Micronized wound care products. The EpiFix products appear to be highly specialized skin substitute products offered for sale to health care professionals, not to the general public. These products currently are regulated by the Food and Drug Administration (as "allograft" products used to replace missing or damaged tissue), and we understand you have also referred the matter to the FDA. As we believe the matter is best handled by the FDA, we will take no further action on the referral at this time. Thank you.

Very truly yours,

A handwritten signature in cursive script that reads "Mary K. Engle".

Mary K. Engle
Associate Director for Advertising Practices